Organogenesis Holdings Inc.
About Organogenesis Holdings Inc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $564.2M
- Net income
- $37.0M
- Total assets
- $598.7M
- Market cap
- $311.4M
- Operating margin
- 7.9%
- Net margin
- 6.6%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $564.2M
- Operating expenses
- $519.5M
- Operating income
- $44.7M
- Income tax
- $9.9M
- Net income
- $37.0M
- EPS (basic)
- $0.16
- EPS (diluted)
- $0.15
Balance sheet
- Total assets
- $598.7M
- Current assets
- $362.2M
- Total liabilities
- $164.8M
- Current liabilities
- $100.1M
- Shareholders’ equity
- $300.1M
Cash flow
- Operating cash flow
- -$10.3M
- Investing cash flow
- -$14.2M
- Financing cash flow
- -$17.4M
- Net cash flow
- -$41.8M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $311.4M
- P/E ratio
- 15.9
- EPS (diluted)
- $0.15
- Shares outstanding
- 130.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 29, 2016
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $37.0M in FY2025.
- Revenue grew 67% from FY2020 to FY2025.
- Trading 64% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 15.9.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Organogenesis Holdings Inc..
Write a review
News about Organogenesis Holdings Inc.
News & sentiment via Polygon.io
